At DuPage Immediate Care, we have started the COVID-19 treatment (Monoclonal Antibody (MAP) Treatment With Bamlanivimab) to our patients under the direction of our infectious disease and pulmonary physicians.


If you’ve recently been diagnosed with COVID-19, you may have a treatment option – it’s called monoclonal antibody (mAb) treatment.

If you already have the virus, mAb treatment gives your body the antibodies it needs to protect itself. Some early evidence suggests that for certain people mAb treatment can reduce the amount of virus in the body and may help their symptoms improve sooner, thereby decreasing the likelihood of them being hospitalized.


Bamlanivimab is a treatment option for people with COVID-19 who:

  • Are age 12 or older

  • Have had mild to moderate symptoms for 10 days or less

  • Are at high risk to get very sick from COVID-19

Adults must meet one of the following criteria

  • Are age 65 or older

  • Have obesity, with a body mass index (BMI) of 35 or higher

  • Have diabetes, chronic kidney disease, or a condition that weakens the immune system

  • Take medication that weakens the immune system

  • Are age 55 or older and have at least one of the following:

  • Heart disease

  • High blood pressure

  • Long-term lung disease

Ages 12-17 (weighing at least 88lbs) must meet at least one of the following criteria

  • Has obesity, with a body mass index (BMI) equal to or greater than 85 percent of children the same age or gender

  • Has heart disease

  • Has sickle cell disease

  • Has a developmental condition, like cerebral palsy

  • Has asthma or a long-term lung disease that requires daily medication for control

  • Regularly uses medical technology, like a ventilator or feeding tube

This drug is not for people who are already in the hospital because of their COVID-19 symptoms. If you’re not sure whether bamlanivimab is right for you, talk with your doctor or contact us. For more information, please refer to the Fact Sheet for Patients, Parents and Caregivers.


First, medical staff will conduct a screening; then you will receive one dose of bamlanivimab by IV infusion through a vein which will take 16 – 60 minutes or longer. Your healthcare provider will determine the duration of your infusion. Afterward, the medical staff will have you stay for another hour to be sure you aren’t having an allergic reaction or other side effects. These reactions are rare, but the staff must observe you for this hour. Then you’ll be released to go home.


When there’s a virus in your body, like COVID-19, your immune system makes antibodies to fight it off. But it takes time for your body to make antibodies for a new virus — and in the meantime, you could get very sick. Bamlanivimab, the drug being used for this treatment, is a drug containing man-made antibodies that are similar to the antibodies of patients who recovered from COVID-19 and it is designed to recognize SARS-CoV-2 (the virus that causes COVID-19). Scientists think that these antibodies may help limit the amount of virus in your body and giving it more time to learn how to make its own antibodies, decreasing the likelihood of getting hospitalized. Bamlanivimab does not have any COVID-19 virus in it.

mAb treatment for COVID-19 is different from a COVID-19 vaccine. A vaccine triggers your body’s natural immune response, but can take weeks to develop enough antibodies and prevent some kinds of infection. Some vaccines for COVID-19 require two shots, so your body can develop its own immune response to the disease. But if you already have the virus, mAb treatment gives your body the antibodies it needs to protect itself.

Read the Fact Sheet for Patients, Parents and Caregivers for more information about bamlanivimab, the drug used in this treatment.